GO
| HSI1 | 23,753.84 | 0.00 | -- |
| HSCEI1 | 7,981.54 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-11-16 15:22:11 Citi said in a report that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding AKESO (09926.HK)'s ivonescimab combined with chemotherapy for advanced non-small cell lung cancer (NSCLC) following EGFR-TKI treatment, stating that HARMONi failed to establish sufficient clinical evidence because the statistically significant progression-free survival (PFS) benefit was not accompanied by a statistically significant improvement in overall survival (OS). The broker believes the HARMONi results may be related to factors such as study design. As the CRL is efficacy-related in nature, there is limited room for resubmission, and focus will shift to other global Phase III studies that may provide clearer OS evidence, with HARMONi-3 being the next key catalyst to watch closely. The broker noted that the FDA's decision will delay potential overseas licensing income and weaken near-term visibility for ivonescimab's commercialization in the US. As a result, the broker lowered its revenue forecasts for FY2027 and FY2028 by 1% and 1%, respectively, and reduced net profit forecasts by 12% and 3%, respectively. It cut the TP from HKD171 to HKD163 and maintained the "Buy" rating. (ha/da)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |